Andere talen Emergent BioSolutions Inc.

Aandelen

EBS

US29089Q1058

Beurs gesloten - Nyse Andere beurzen 22:00:02 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,04 ^USD	+9,68%		-0,97%	-15,00%

25/03	Emergent krijgt de "No Action Indicated" status van de FDA voor de productiefaciliteit in Baltimore Bayview	MT
25/03	Emergent Biosolutions ontvangt NAI-status voor productiefaciliteit Baltimore Bayview	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis	28/03
Emergent Gets FDA's 'No Action Indicated' Status For Baltimore Bayview Manufacturing Facility	25/03
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility	25/03
Emergent Biosolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility	25/03
Sector Update: Health Care Stocks Rise Late Afternoon	12/03
Sector Update: Health Care Stocks Higher in Afternoon Trading	12/03
Emergent BioSolutions Tumbles After S&P Global Credit Downgrade	12/03
Emergent BioSolutions Shares Drop on S&P Downgrade	12/03
North American Morning Briefing : Stock Futures -2-	08/03
News Highlights : Top Company News of the Day - Thursday at 1 AM ET	07/03
News Highlights : Top Company News of the Day - Wednesday at 11 PM ET	07/03
News Highlights : Top Company News of the Day - Wednesday at 9 PM ET	07/03
News Highlights : Top Company News of the Day - Wednesday at 7 PM ET	07/03
Emergent Biosolutions: Q4 Earnings Snapshot	06/03
(EBS) EMERGENT BIOSOLUTIONS Sees Q1 Revenue Range $200M - $250M	06/03
Earnings Flash (EBS) EMERGENT BIOSOLUTIONS Reports Q4 Revenue $277M, vs. Street Est of $274M	06/03
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results	06/03
Emergent BioSolutions Inc. Provides Revenue Guidance for the First Quarter and Earnings Guidance for the Full Year of 2024	06/03
Emergent BioSolutions Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03
Emergent BioSolutions Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	06/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Emergent BioSolutions Inc.

Aandelen

EBS

US29089Q1058

Andere talen

Filters